Placebo to Grazoprevir

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Hepatitis CHepatitis C VirusHepatitis C, Chronic

Phase 2

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

TerminatedNCT01440595

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2011-11-28End: 2012-05-01Updated: 2024-05-22

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

CompletedNCT02092350

Merck Sharp & Dohme LLCHepatitis C Virus

Start: 2014-03-17End: 2015-09-02Updated: 2018-09-24

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

CompletedNCT02203149

Merck Sharp & Dohme LLCHepatitis C

Start: 2014-08-01End: 2016-05-16Updated: 2018-09-24

Related Papers

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.

2019-01-258 citations

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

2018-01-1736 citations

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

Hepatology Communications2017-08-229 citations

Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

2017-05-3057 citations

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.

2017-02-1159 citations

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.

2016-11-2160 citations

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

2015-10-05492 citations